CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone41-41-561-3277
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.12 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings data on Monday, February, 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.83) by $0.09. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.56 million. Crispr Therapeutics had a negative return on equity of 48.35% and a negative net margin of 5,281.08%. The company's revenue for the quarter was down 99.7% on a year-over-year basis. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
10 analysts have issued twelve-month target prices for Crispr Therapeutics' shares. Their predictions range from $21.00 to $72.50. On average, they anticipate Crispr Therapeutics' share price to reach $46.7033 in the next year. This suggests a possible upside of 34.1% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.
What is the consensus analysts' recommendation for Crispr Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Crispr Therapeutics.
What are Wall Street analysts saying about Crispr Therapeutics stock?
Here are some recent quotes from research analysts about Crispr Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (3/13/2019)
- 2. William Blair analysts commented, "CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39 fair value estimate. While we acknowledge the innovative nature of the CRISPR/Cas9 discovery and the ease of use and flexibility of the platform as a potential ex vivo and in vivo therapeutic modality, we view the most-progressed indications being targeted—beta-thalassemia and sickle cell with CTX001 in col- laboration with Vertex and allogeneic T-cell therapy for hematological malignancies (acute lymphocytic leukemia [ALL], non-Hodgkin lymphoma [NHL], and multiple myeloma [MM])—as hyper-competitive spaces where the company is behind the leaders in clinical development." (3/13/2019)
Has Crispr Therapeutics been receiving favorable news coverage?
Media headlines about CRSP stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crispr Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX) and Rubius Therapeutics (RUBY).
What other stocks do shareholders of Crispr Therapeutics own?
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Mr. Michael John Tomsicek M.B.A, Chief Financial Officer (Age 53)
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)
- Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
- Dr. Samarth Kulkarni, CEO & Director (Age 40)
- Dr. Chad Cowan, Scientific Founder
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.23%), Ontario Teachers Pension Plan Board (1.12%), Two Sigma Investments LP (0.98%), Two Sigma Advisers LP (0.91%), Global Thematic Partners LLC (0.86%) and FMR LLC (0.61%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics.
Which institutional investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Global Thematic Partners LLC, Jane Street Group LLC, WS Management Lllp, Bank of New York Mellon Corp, UBS Oconnor LLC and UBS Oconnor LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.
Which institutional investors are buying Crispr Therapeutics stock?
CRSP stock was bought by a variety of institutional investors in the last quarter, including Ontario Teachers Pension Plan Board, Alps Advisors Inc., Two Sigma Investments LP, Voloridge Investment Management LLC, Two Sigma Advisers LP, SHANDA ASSET MANAGEMENT HOLDINGS Ltd, California Public Employees Retirement System and Artal Group S.A.. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer and Vertex Pharmaceuticals (Europe. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $34.83.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $1.82 billion and generates $3.12 million in revenue each year. The company earns $-164,980,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis.
What is Crispr Therapeutics' official website?
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]
MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
